A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

• Main Authors: Gi-Ae Kim (Author), Hyun Chin Cho (Author), Soung Won Jeong (Author), Bo-Kyeong Kang (Author), Mimi Kim (Author), Seungwon Jung (Author), Jungwook Hwang (Author), Eileen L. Yoon (Author), Dae Won Jun (Author)
• Formato: Libro
• Publicado: MDPI AG, 2023-04-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Preclinical data have shown that the herbal extract, ALS-L1023, from <i>Melissa officinalis</i> reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week random...